# US 2018/0022780 A1 · Stabilization adrenomedullin derivatives and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022780 A1
- Document ID: US20180022780A1
- Status: Published application
- Kind: A1
- Application number: 15/514,456
- Filed: 2015-09-24
- Published: 2018-01-25
- Earliest claimed: 2014-09-26
- Assignees: Bayer Pharma Aktiengesellschaft
- Applicants: Bayer Pharma Aktiengesellschaft
- Inventors: Donald BIERER; Ingo FLAMME; Johannes KÖBBERLING; Bernd RIEDL; Annette BECK-SICKINGER; Ria SCHOENAUER; Jan-Patrick FISCHER
- Web page: https://patentgrep.com/patent/US20180022780A1

## CPC

- C07K 14/001: {by chemical synthesis}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/55: Protease inhibitors
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/04: Antipruritics
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to novel, biologically active, stabilized Adrenomedullin (ADM) compounds. The invention further relates to the compounds for use in a method for the treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, and to medicaments comprising the compounds for treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.

## Claims

### Claim 1

A compound of formula (I)
wherein X1 is selected from the group consisting of
*—(CH2)m1—S—#, wherein m1 is 0-6; #—(CH2)m2—S—*, wherein m2 is 0-6;
*—(CH2)m3—#, wherein m3 is 1-8;
*—(CH2)m4—(CH2═CH2)—(CH2)n1—#, wherein m4 is 0-6, n1 is 0-6, with the proviso that m4+n1=0-6;
*—(CH2)m5—(CH≡CH)—(CH2)n2—#, wherein m5 is 0-6, and n2 is 0-6, with the proviso that m5+n2=0-6;
*—(CH2)m6—CO—NH—(CH2)n3—#, wherein m6 is 0-4, and n3 is 0-4, with the proviso that m6+n3=0-6; #—(CH2)m7—CO—NH—(CH2)n4—*, wherein m7 is 0-4, and n4 is 0-4, with the proviso that m7+n4=0-6;
*—SO—(CH2)m8—#, wherein m8 is 0-6; #—SO—(CH2)m9—*, wherein m9 is 0-6;
*—SO2—(CH2)m10—#, wherein m10 is 0-6; #—SO2—(CH2)m11—*, wherein m11 is 0-6;
*-5-6 membered heteroaryl-#;
*—O—(CH2)m12—#, wherein m12 is 0-6; #—O—(CH2)m13—*, wherein m13 is 0-6;
*—CH2—S—(CH2)m14—#, wherein m14 is 0-6; #—CH2—S—(CH2)m15—*, wherein m15 is 0-6;
*—CH2—O—(CH2)m16—#, wherein m16 is 0-6; #—CH2—O—(CH2)m17—*, wherein m17 is 0-6;
*—(CH2)m18—NH—CO—CH2—NH—CO—(CH2)n5—#, wherein m18 is 0-3, and n5 is 0 or 1, with the proviso that m18+n5=0-3; #—(CH2)m19—NH—CO—CH2—NH—CO—(CH2)n6—*, wherein m19 is 0-3, and n6 is 0 or 1, with the proviso that m19+n6=0-3;
*—(CH2)m20—NH—CO—CH(CH3)—NH—CO—(CH2)n7—#, wherein m20 is 0-3, and n7 is 0 or 1, with the proviso that m20+n7=0-3; #—(CH2)m21—NH—CO—CH(CH3)—NH—CO—(CH2)n8—*, wherein m21 is 0-3, and n8 is 0 or 1, with the proviso that m21+n8=0-3;
*—(CH2)m22—NH—CO—CH(CH2—C(CH3)2)—NH—CO—(CH2)n9—#, wherein m22 is 0-3, and n9 is 0 or 1, with the proviso that m22+n9=0-3; #—(CH2)m23—NH—CO—CH(CH2—C(CH3)2)—NH—CO—(CH2)n10—*, wherein m23 is 0-3, and n10 is 0 or 1, with the proviso that m23+n10=0-3;
*—(CH2)m24—NH—CO—CH(CH(CH3)C2H5)—NH—CO—(CH2)n11—#, wherein m24 is 0-3, and n11 is 0 or 1, with the proviso that m24+n11=0-3; #—(CH2)m25—NH—CO—CH(CH(CH3)C2H5)—NH—CO—(CH2)n12—*, wherein m25 is 0-3, and n12 is 0 or 1, with the proviso that m25+n12=0-3;
*—(CH2)m26—NH—CO—CH(CH2(C6H5))—NH—CO—(CH2)n—#, wherein m26 is 0-3, and n13 is 0 or 1, with the proviso that m26+n13=0-3; #—(CH2)m27—NH—CO—CH(CH2(C6H5))—NH—CO—(CH2)n14—*, wherein m27 is 0-3, and n14 is 0 or 1, with the proviso that m27+n14=0-3;
*—(CH2)m28—NH—CO—(CH2)3—NH—CO—(CH2)n15—#, wherein m28 is 0 or 1, and n15 is 0 or 1, with the proviso that m28+n15=0-1; #—(CH2)m29—NH—CO—(CH2)3—NH—CO—(CH2)n16—*, wherein m29 is 0 or 1, and n16 is 0 or 1, with the proviso that m29+n16=0-1;
*—(CH2)m30—NH—CO—NH—(CH2)n17—#, wherein m30 is 0-5, and n17 is 0-5, with the proviso that m30+n17=0-5; #—(CH2)m31—NH—CO—NH—(CH2)n18—*, wherein m31 is 0-5, and n18 is 0-5, with the proviso that m31+n18=0-5;
*—(CH2)m32—O—CO—NH—(CH2)n19—#, wherein m32 is 0-5, and n19 is 0-5, with the proviso that m32+n19=0-5; #—(CH2)m33—O—CO—NH—(CH2)n20—*, wherein m33 is 0-5, and n20 is 0-5, with the proviso that m33+n20=0-5;
*—(CH2)m34—O—CO—O—(CH2)n21—#, wherein m 34 is 0-5, and n21 is 0-5, with the proviso that m34+n21=0-5;
*—(CH2)m35—NH—CO—(CH2)n22—NH—(CH2)p1—, wherein m35 is 0-4, n22 is 0-4, and p1 is 0-4, with the proviso that m35+n22+p1=0-4; and
*—(CH2)m36—NH—CO—(CH═CH)—CO—NH—(CH2)n23—#, wherein m36 is 0-2, and n23 is 0-2, with the proviso that m36+n23=0-2;
wherein * and # reflect where X1 is bound within the ring structure; and
X2 is absent, is hydrogen, or is an amino acid or amino acid sequence selected from the group consisting of G14, K14, F14, SEQ ID NO: 1 [Y1RQSMNNFQGLRSF14], SEQ ID NO: 2 [R2QSMNNFQGLRSF14], SEQ ID NO: 3 [Q3SMNNFQGLRSF14], SEQ ID NO: 4 [S4MNNFQGLRSF14], SEQ ID NO: 5 [M5NNFQGLRSF14], SEQ ID NO: 6 [N6NFQGLRSF14], SEQ ID NO: 7 [N7FQGLRSF14], SEQ ID NO: 8 [F8QGLRSF14], SEQ ID NO: 9 [Q9GLRSF14], SEQ ID NO: 10 [G10LRSF14], SEQ ID NO: 11 [L11RSF14], SEQ ID NO: 12 [R12SF14], and SEQ ID NO: 13 [S13F14], which is covalently linked by an amide bond to the N-terminal G15 of the amino acid sequence of formula (I), wherein any amino acid of X2 may optionally be replaced by a natural or unnatural amino acid;
wherein A is L-Alanine; R is L-Arginine; N is L-Asparagine; D is L-Aspartic acid; Q is L-Glutamine; G is L-Glycine; H is L-Histidine; I is L-Isoleucine; L is L-Leucine; K is L-Lysine; M is L-Methionine; F is L-Phenylalanine; P is L-Proline; S is L-Serine; T is L-Threonine; Y is L-Tyrosine; V is L-Valine;
wherein the numbering of amino acids in formula (I) and in the definition of X2 refers to the corresponding human ADM sequence;
X3 is absent or is a heterologous moiety which is covalently linked to the N-terminus or to a functional group of the side chain of any amino acid of X2, to the N-terminus of G15 or to Z;
Z is absent or is a cleavable linker covalently bound between the N terminus of any amino acid of X2 or of G15 and X3 or between a functional group of the side chain of any amino acid of X2 and X3
wherein if X3 is absent, then
Z is also absent and X2 is hydrogen or is an amino acid or amino acid sequence as defined above;
wherein if X3 is a heterologous moiety, then
X2 is absent or is an amino acid or amino acid sequence as defined above; Z is absent or is a cleavable linker covalently bound between the N terminus of any amino acid of X2 or of G15 and X3 or between a functional group of the side chain of any amino acid of X2 and X3;
or a physiologically acceptable salt, a solvate or a solvate of a salt thereof.

### Claim 2 (depends on 1)

The compound of formula (I) as claimed in claim 1, wherein X1 is selected from the group consisting of
*—(CH2)m1—S—#, wherein m1 is 0-6; #—(CH2)m2—S—*, wherein m2 is 0-6;
*—(CH2)m3—#, wherein m3 is 1-8;
*—(CH2)m6—CO—NH—(CH2)n3—#, wherein m6 is 0-4, and n3 is 0-4, with the proviso that m6+n3=0-6; #—(CH2)m7—CO—NH—(CH2)n4—*, wherein m7 is 0-4, and n4 is 0-4, with the proviso that m7+n4=0-6;
X2 is G14 or K14, which is covalently linked by an amide bond to the N-terminal G15 of the compound of formula (I);
X3 is absent or is a heterologous moiety which is covalently linked to the N-terminus of G14 or K14 or to a functional group of the side chain of K14, or to Z;
Z is absent or is a cleavable linker covalently bound between the N terminus of G14 or K14 and X3, or between a functional group of the side chain of K14 and X3;
wherein if X3 is absent, then Z is also absent;
wherein if X3 is a heterologous moiety, then Z is absent or is a cleavable linker covalently bound between the N terminus of G14 or K14 and X3, or between a functional group of the side chain of K14 and X3;
or a physiologically acceptable salt, a solvate or a solvate of a salt thereof.

### Claim 3 (depends on 1)

The compound of formula (I) as claimed in claim 1, wherein X3 is a heterologous moiety selected from the group consisting of a polymer, a Fc, a FcRn binding ligand, albumin and an albumin-binding ligand;
or a physiologically acceptable salt, a solvate or a solvate of a salt thereof.

### Claim 4 (depends on 3)

The compound of formula (I) as claimed in claim 3, wherein X3 is a polymer and the polymer is selected from the group consisting of linear or branched C3-C100 carboxylic acids, preferably C4-C30 carboxylic acids, optionally substituted with halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, sulfate, or phosphate, and which may be saturated, or mono- or di-unsaturated, a PEG moiety, a PPG moiety, a PAS moiety and a HES moiety;
or a physiologically acceptable salt, a solvate or a solvate of a salt thereof.

### Claim 5 (depends on 4)

The compound of formula (I) as claimed in claim 4, wherein the carboxylic acid is selected from the group consisting of arachidic acid, arachidonic acid, behenic acid, capric acid, caproic acid, caprylic acid, ceroplastic acid, cerotic acid, docosahexaenoic acid, eicosapentaenoic acid, elaidic acid, enanthic acid, erucic acid, geddic acid, henatriacontylic acid, heneicosylic acid, heptacosylic acid, hexatriacontylic acid, lacceroic acid, lauric acid, lignoceric acid, linoelaidic acid, linoleic acid, margaric acid, melissic acid, montanic acid, myristic acid, myristoleic acid, nonacosylic acid, nonadecylic acid, oleic acid, palmitic acid, palmitoleic acid, pantothenic acid, pelargonic acid, pentacosylic acid, pentadecylic acid, psyllic acid, sapienic acid, stearic acid, tricosylic acid, tridecylic acid, undecylic acid, vaccenic acid, valeric acid, α-linolenic acid and derivatives thereof;
or a physiologically acceptable salt, a solvate or a solvate of a salt thereof.

### Claim 6 (depends on 1)

The compound of formula (I) as claimed in claim 1, wherein Z is absent;
or a physiologically acceptable salt, a solvate or a solvate of a salt thereof.

### Claim 7 (depends on 1)

The compound of formula (I) as claimed in claim 1, wherein Z is a cleavable linker;
or a physiologically acceptable salt, a solvate or a solvate of a salt thereof.

### Claim 8 (depends on 1)

The compound of formula (I) as claimed claim 1, wherein the compound is further modified by N-methylation of at least one amide bond;
or a physiologically acceptable salt, a solvate or a solvate of a salt thereof.

### Claim 9 (depends on 1)

The compound of formula (I) as claimed in claim 1, wherein
X1 is selected from the group consisting of *—(CH2)m1—S—#, wherein m1 is 0-4; #—(CH2)m2—S—*, wherein m2 is 0-4; *—(CH2)m6—CO—NH—(CH2)n3—#, wherein m6 is 0-4, and n3 is 0-4, with the proviso that m6+n3=0-6;
X2 is G14 or K14, which is covalently linked by an amide bond to the N-terminal G15 of the compound of formula (I);
X3 is absent or is a heterologous moiety which is covalently linked to the N-terminus of G14 or K14 or to a functional group of the side chain of K14, or to Z;
Z is absent or is a cleavable linker covalently bound between the N terminus of G14 or K14 and X3, or between a functional group of the side chain of K14 and X3;
wherein if X3 is absent, then Z is also absent;
wherein if X3 is a heterologous moiety, then Z is absent or is a cleavable linker covalently bound between the N terminus of G14 or K14 and X3, or between a functional group of the side chain of K14 and X3;
or a physiologically acceptable salt, a solvate or a solvate of a salt thereof.

### Claim 10 (depends on 1)

A compound as claimed in claim 1 for use in a method for the treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.

### Claim 11 (depends on 1)

The compound as claimed in claim 1 for use in a method for the treatment and/or prevention of heart failure, chronic heart failure, worsening heart failure, acute heart failure, acute decompensated heart failure, diastolic and systolic (congestive) heart failure, coronary heart disease, ischemic and/or hemorrhagic stroke, hypertension, pulmonary hypertension, peripheral arterial occlusive disease, pre-eclampsia, chronic obstructive pulmonary disease, asthma, acute and/or chronic pulmonary edema, allergic alveolitis and/or pneumonitis due to inhaled organic dust and particles of fungal, actinomycetic or other origin, and/or acute chemical bronchitis, acute and/or chronic chemical pulmonary edema, neurogenic pulmonary edema, acute and/or chronic pulmonary manifestations due to radiation, acute and/or chronic interstitial lung disorders, acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in adult or child including newborn, ALI/ARDS secondary to pneumonia and sepsis, aspiration pneumonia and ALI/ARDS secondary to aspiration, ALI/ARDS secondary to smoke gas inhalation, transfusion-related acute lung injury (TRALI), ALI/ARDS and/or acute pulmonary insufficiency following surgery, trauma and/or burns, and/or ventilator induced lung injury (VILI), lung injury following meconium aspiration, pulmonary fibrosis, mountain sickness, chronic kidney diseases, glomerulonephritis, acute kidney injury, cardiorenal syndrome, lymphedema, inflammatory bowel disease, sepsis, septic shock, systemic inflammatory response syndrome (SIRS) of non-infectious origin, anaphylactic shock, inflammatory bowel disease, urticaria and/or edematous ocular disorders or ocular disorders associated with disturbed vascular function.

### Claim 12 (depends on 1)

A medicament comprising a compound as claimed in claim 1 in combination with an inert nontoxic pharmaceutically suitable excipient.

### Claim 13 (depends on 1)

A medicament comprising a compound as claimed in claim 1 in combination with a further active ingredient selected from the group consisting of ACE inhibitors, angiotensin receptor antagonists, beta-2 receptor agonists, phosphodiesterase (PDE) inhibitors, glucocorticoid receptor agonists, diuretics, recombinant angiotensin converting enzyme-2, acetylsalicylic acid, natriuretic peptides and derivatives thereof, and neprilysin inhibitors.

### Claim 14 (depends on 12)

The medicament as claimed in claim 12 for the treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.

### Claim 15 (depends on 1)

Method for the treatment and/or prophylaxis of cardiovascular, edematous and/or inflammatory disorders in humans or animals using an effective amount of at least one compound as claimed in claim 1, or a medicament comprising the at least one compound in combination with an inert nontoxic pharmaceutically suitable excipient.

### Claim 16 (depends on 11)

The compound as claimed in claims 11, wherein the use is a method for the treatment and/or prevention of age-related macular degeneration (AMD) or diabetic retinopathy.

### Claim 17 (depends on 16)

The compound as claimed in claim 16, wherein the use is a method for the treatment and/or prevention of diabetic macula edema (DME), subretinal edema or intraretinal edema.
